Department of Obstetrics and Gynecology, Po-Jen General Hospital, Taipei, Taiwan.
Arch Gynecol Obstet. 2011 Sep;284(3):721-9. doi: 10.1007/s00404-010-1708-6. Epub 2010 Nov 3.
HER2 gene amplification and HER2 protein overexpression are important factors in predicting clinical sensitivity to anti-HER2 monoclonal antibody therapy in breast cancer patients. The purpose of this study is to evaluate the correlation between HER2 protein expressions and the HER2 gene copies per tumor cell either before or after chromosome-17 correction in epithelial ovarian cancer (EOC).
Adopting 2007 ASCO/CAP guideline recommendations for HER2 testing, 27 tissue microarray (TMA) samples from EOC patients were analyzed by immunohistochemistry (IHC) using Dako, c-erb-B2 antibody and subsequently examined by fluorescence in situ hybridization (FISH) using Abbott/Vysis, PathVysion HER2 DNA Probe Kit.
The overall concordance revealed 81.5% between HER2 IHC and HER2 FISH results. Additionally, HER2 gene copies prior to chromosome-17 correction increased significantly in a stepwise order through the negative, equivocal, and positive IHC result categories (P = 0.026), as did the HER2 gene copies after chromosome-17 correction (P = 0.028). On the other hand, HER2 IHC results correlated significantly with both chromosome-17 uncorrected HER2 gene copy numbers (ρ = 0.430, P = 0.025) and chromosome-17 corrected HER2 gene copy numbers (ρ = 0.524, P = 0.027).
We demonstrated that both chromosome-17 corrected and uncorrected HER2 gene copies correlated significantly with HER2 IHC result categories; and tests for the HER2 gene copies per tumor cell either before or after correction for chromosome-17 can be applied as a potentially valuable tool in analyzing the HER2 status in EOC.
HER2 基因扩增和 HER2 蛋白过表达是预测乳腺癌患者抗 HER2 单克隆抗体治疗临床敏感性的重要因素。本研究旨在评估上皮性卵巢癌（EOC）中 HER2 蛋白表达与肿瘤细胞中 HER2 基因拷贝数在染色体 17 校正前后的相关性。
采用 2007 年 ASCO/CAP 指南推荐的 HER2 检测方法，对 27 例 EOC 患者的组织微阵列（TMA）样本进行免疫组织化学（IHC）分析，使用 Dako、c-erb-B2 抗体，随后使用 Abbott/Vysis、PathVysion HER2 DNA Probe Kit 进行荧光原位杂交（FISH）检测。
HER2 IHC 和 HER2 FISH 结果的总符合率为 81.5%。此外，在阴性、不确定和阳性 IHC 结果类别中，未经染色体 17 校正的 HER2 基因拷贝数呈逐步增加趋势（P = 0.026），经染色体 17 校正的 HER2 基因拷贝数也呈增加趋势（P = 0.028）。另一方面，HER2 IHC 结果与未经染色体 17 校正的 HER2 基因拷贝数（ρ=0.430，P=0.025）和经染色体 17 校正的 HER2 基因拷贝数（ρ=0.524，P=0.027）均显著相关。
我们证明了未经染色体 17 校正和校正后的 HER2 基因拷贝数与 HER2 IHC 结果类别显著相关；对未经染色体 17 校正和校正后的肿瘤细胞中 HER2 基因拷贝数的检测可作为分析 EOC 中 HER2 状态的一种有价值的工具。
